PT1439175E - Composto pirimidina e sua composição medicinal - Google Patents
Composto pirimidina e sua composição medicinal Download PDFInfo
- Publication number
- PT1439175E PT1439175E PT02802050T PT02802050T PT1439175E PT 1439175 E PT1439175 E PT 1439175E PT 02802050 T PT02802050 T PT 02802050T PT 02802050 T PT02802050 T PT 02802050T PT 1439175 E PT1439175 E PT 1439175E
- Authority
- PT
- Portugal
- Prior art keywords
- substituted
- group
- carbon atoms
- aromatic heterocyclic
- atom
- Prior art date
Links
- -1 Pyrimidine compound Chemical class 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 12
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 108050000203 Adenosine receptors Proteins 0.000 abstract 1
- 102000009346 Adenosine receptors Human genes 0.000 abstract 1
- 101150078577 Adora2b gene Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001324018 | 2001-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1439175E true PT1439175E (pt) | 2011-07-08 |
Family
ID=19140824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02802050T PT1439175E (pt) | 2001-10-22 | 2002-10-22 | Composto pirimidina e sua composição medicinal |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7396836B2 (OSRAM) |
| EP (2) | EP2246344A1 (OSRAM) |
| JP (1) | JP4462930B2 (OSRAM) |
| KR (1) | KR100884025B1 (OSRAM) |
| CN (1) | CN100519549C (OSRAM) |
| AT (1) | ATE507217T1 (OSRAM) |
| AU (1) | AU2002335536B2 (OSRAM) |
| BR (1) | BR0213455A (OSRAM) |
| CA (1) | CA2463284C (OSRAM) |
| CY (1) | CY1112341T1 (OSRAM) |
| DE (1) | DE60239884D1 (OSRAM) |
| DK (1) | DK1439175T3 (OSRAM) |
| ES (1) | ES2364328T3 (OSRAM) |
| HU (1) | HUP0401950A3 (OSRAM) |
| IL (2) | IL161493A0 (OSRAM) |
| MX (1) | MXPA04003795A (OSRAM) |
| NO (1) | NO327581B1 (OSRAM) |
| NZ (1) | NZ532373A (OSRAM) |
| PL (1) | PL215572B1 (OSRAM) |
| PT (1) | PT1439175E (OSRAM) |
| RU (1) | RU2288227C2 (OSRAM) |
| TW (1) | TWI330183B (OSRAM) |
| WO (1) | WO2003035639A1 (OSRAM) |
| ZA (1) | ZA200402898B (OSRAM) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI330183B (OSRAM) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| ES2229928B1 (es) * | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
| GB0323137D0 (en) * | 2003-10-03 | 2003-11-05 | Chang Lisa C W | 2,4,6- Trisubstituted pyrimidines and their different uses |
| GB0323138D0 (en) * | 2003-10-03 | 2003-11-05 | Chang Lisa C W | Pyrimidines substituted in the 2,4,6 positions and their different uses |
| EP1679309A4 (en) * | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
| WO2005040151A1 (en) * | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| MXPA06006776A (es) * | 2003-12-15 | 2007-03-23 | Almirall Prodesfarma Ag | 2,6-bisheteroaril-4-aminopirimidinas como antagonistas del receptor de adenosina. |
| BRPI0418082B8 (pt) | 2003-12-26 | 2021-05-25 | Kyowa Hakko Kirin Co Ltd | derivados de tiazol úteis como antagonistas de receptor de adenosina a2a |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| GB2416125A (en) * | 2004-07-15 | 2006-01-18 | Michael James Hill | Device for supplying fluid to an ear |
| JP2008520744A (ja) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
| GB0428514D0 (en) * | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| EP2210889A1 (en) | 2005-03-21 | 2010-07-28 | Eisai R&D Management Co., Ltd. | Process for producing pyrimidine compound |
| US7538117B2 (en) | 2005-03-21 | 2009-05-26 | Eisai R&D Management Co., Ltd. | Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds |
| US7396928B2 (en) | 2005-03-21 | 2008-07-08 | Eisai R&D Management Co., Ltd. | Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same |
| US20080275064A1 (en) * | 2005-04-11 | 2008-11-06 | Deborah Slee | Substituted Pyrimidines as Adenosine Receptor Antagonists |
| PH12012502411A1 (en) | 2005-05-10 | 2019-07-17 | Intermune Inc | Method of modulating stress-activated protein kinase system |
| US20100280023A1 (en) | 2005-06-23 | 2010-11-04 | Kyowa Hakko Kogyo Co., Ltd. | Thiazole derivatives |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| DK1921077T3 (en) | 2005-08-02 | 2017-10-23 | Kyowa Hakko Kirin Co Ltd | Means for treating and / or preventing sleep disorders |
| ES2274712B1 (es) * | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| US20070287707A1 (en) * | 2006-02-28 | 2007-12-13 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| DK2004654T3 (da) | 2006-04-04 | 2013-07-22 | Univ California | Pyrazolopyrimidin derivater til anvendelse som kinase antagonister |
| US20080009623A1 (en) * | 2006-07-06 | 2008-01-10 | Eisai R&D Management Co., Ltd. | Pyrimidine compounds |
| JP2009286694A (ja) * | 2006-09-07 | 2009-12-10 | Eisai R & D Management Co Ltd | ５−［２−アミノ−４−（２−フリル）ピリミジン−５−イル］−１−メチルピリジン−２（１ｈ）−オンの塩およびそれらの結晶 |
| ES2303776B1 (es) * | 2006-12-29 | 2009-08-07 | Laboratorios Almirall S.A. | Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b. |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| KR20100025006A (ko) * | 2007-07-26 | 2010-03-08 | 노파르티스 아게 | 염증성 또는 알레르기성 질병의 치료에 유용한 피리미딘 유도체 |
| TWI475995B (zh) | 2007-09-14 | 2015-03-11 | 詹森藥物公司 | １’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物 |
| WO2009046448A1 (en) * | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| KR101660050B1 (ko) | 2008-01-04 | 2016-09-26 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| WO2009114870A2 (en) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
| BRPI0909157A2 (pt) | 2008-03-26 | 2015-11-24 | Advinus Therapeutics Private Ltd | compostos heterocíclicos como antagonistas de receptores de adenosina |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| CN101343253B (zh) * | 2008-06-24 | 2011-03-16 | 陕西师范大学 | 2-氨基-4,5-二芳基嘧啶类化合物及其制备方法和药物用途 |
| EP3009436B1 (en) | 2008-07-08 | 2019-06-05 | Intellikine, LLC | Kinase inhibitors and methods of use |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| MX2011002042A (es) | 2008-09-02 | 2011-06-20 | Ortho Mcneil Janssen Pharm | Derivados de 3-azabiciclo[3.1.o]hexilo como moduladores de los receptores del glutamato metabotropico. |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| ES2570429T3 (es) | 2008-10-16 | 2016-05-18 | Univ California | Inhibidores de heteroaril quinasa de anillo condensado |
| US8476431B2 (en) * | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
| RU2512283C2 (ru) | 2008-11-28 | 2014-04-10 | Янссен Фармасьютикалз, Инк. | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов |
| AU2010222289B2 (en) | 2009-03-13 | 2013-07-11 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| AR076859A1 (es) | 2009-05-12 | 2011-07-13 | Ortho Mcneil Janssen Pharm | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| WO2011055391A1 (en) | 2009-11-09 | 2011-05-12 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| KR20130044381A (ko) * | 2010-03-04 | 2013-05-02 | 머크 샤프 앤드 돔 코포레이션 | 카테콜 ｏ－메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도 |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| EP2571357B1 (en) | 2010-05-21 | 2016-07-06 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| EP2616470B1 (en) | 2010-09-13 | 2016-10-12 | Advinus Therapeutics Limited | Purine compounds as prodrugs of a2b adenosine receptor antagonists, their process and medicinal applications |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US8906933B2 (en) | 2010-09-24 | 2014-12-09 | N30 Pharmaceuticals, Inc. | Dihydropyrimidin-2(1H)-one compounds as neurokinin-3 receptor antagonists |
| CN103298810B (zh) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| WO2012062751A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| NZ612909A (en) | 2011-01-10 | 2015-09-25 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| JP6130305B2 (ja) | 2011-02-23 | 2017-05-17 | インテリカイン， エルエルシー | キナーゼ阻害剤の組み合わせおよびそれらの使用 |
| CZ305457B6 (cs) * | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| CN103930422A (zh) | 2011-07-19 | 2014-07-16 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
| AU2012302197B2 (en) | 2011-08-29 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途 |
| KR102093526B1 (ko) | 2012-03-01 | 2020-03-25 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 억제제 |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| WO2014052669A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| MX386085B (es) | 2012-11-01 | 2025-03-18 | Infinity Pharmaceuticals Inc | Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa |
| US9273033B2 (en) | 2012-11-20 | 2016-03-01 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as PDE10 inhibitors |
| KR101529496B1 (ko) * | 2012-12-27 | 2015-06-22 | 한국과학기술원 | 낮은 열팽창 계수를 갖는 신규한 폴리아미드이미드 |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN109999025A (zh) | 2014-01-21 | 2019-07-12 | 詹森药业有限公司 | 包括代谢型谷氨酸能受体亚型2的正别构调节物或正位激动剂的组合及其用途 |
| IL279202B2 (en) | 2014-01-21 | 2023-09-01 | Janssen Pharmaceutica Nv | Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use |
| EP3138839B1 (en) | 2014-02-14 | 2020-10-28 | Sichuan Haisco Pharmaceutical Co., Ltd. | Pyridone or pyrimidone derivative, preparation method therefor and application thereof |
| CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
| KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| CA2998469C (en) | 2015-09-14 | 2025-12-09 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
| JP2017149663A (ja) * | 2016-02-24 | 2017-08-31 | 株式会社Ｌｔｔバイオファーマ | 過敏性腸症候群治療剤 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112018077021A2 (pt) | 2016-06-24 | 2019-04-02 | Infinity Pharmaceuticals, Inc. | terapias de combinação |
| NZ754731A (en) * | 2017-01-20 | 2023-02-24 | Arcus Biosciences Inc | Azolopyrimidine for the treatment of cancer-related disorders |
| PT3611174T (pt) * | 2017-04-07 | 2022-07-07 | Medshine Discovery Inc | Derivado de [1,2,4]triazolo[1,5-c]pirimidina como inibidor do recetor a2a |
| WO2018204661A1 (en) * | 2017-05-05 | 2018-11-08 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| JP7417527B2 (ja) | 2018-02-16 | 2024-01-18 | アーカス バイオサイエンシズ インコーポレイティド | アゾロピリミジン化合物による投薬 |
| CN110240593A (zh) * | 2018-03-09 | 2019-09-17 | 四川科伦博泰生物医药股份有限公司 | 取代芳胺化合物及其制备方法和用途 |
| CN108314631A (zh) * | 2018-04-19 | 2018-07-24 | 中国科学院昆明植物研究所 | 二芳基乙烯类化合物及其药物组合物和其应用 |
| CN110655509B (zh) * | 2018-06-29 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN110684020B (zh) * | 2018-07-05 | 2023-01-20 | 江苏恒瑞医药股份有限公司 | 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN112423758A (zh) * | 2018-07-10 | 2021-02-26 | 尼康治疗公司 | 腺苷受体结合化合物 |
| WO2020011220A1 (zh) * | 2018-07-12 | 2020-01-16 | 江苏恒瑞医药股份有限公司 | 杂芳基类衍生物、其制备方法及其在医药上的应用 |
| WO2020135210A1 (zh) * | 2018-12-28 | 2020-07-02 | 四川科伦博泰生物医药股份有限公司 | 取代芳基化合物及其制备方法和用途 |
| US20220017483A1 (en) | 2018-12-28 | 2022-01-20 | Sichuan-Kelun-Biotech Biopharmaceutical Co., Ltd | Aminopyridine compound, preparation method therefor and use thereof |
| CN111377873B (zh) * | 2018-12-28 | 2023-03-28 | 四川科伦博泰生物医药股份有限公司 | 氨基嘧啶化合物及其制备方法和用途 |
| US10689374B1 (en) | 2019-07-12 | 2020-06-23 | United Arab Emirates University | Pyrimidine-thiazolidinone derivatives |
| US10702525B1 (en) | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
| KR20220147124A (ko) * | 2020-03-16 | 2022-11-02 | 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 | 치환된 피리미딘 또는 피리딘 아민 유도체, 이의 조성물 및 의약적 용도 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3029426A1 (de) * | 1980-08-02 | 1982-03-11 | Bayer Ag, 5090 Leverkusen | Gegen zwecken wirksame pour-on-formulierungen |
| US4725600A (en) * | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
| FR2584925B1 (fr) * | 1985-07-17 | 1987-11-27 | Bosserelle Micheline | Composition de corps gras d'origine vegetale pour usage cosmetique |
| US4927813A (en) * | 1988-03-08 | 1990-05-22 | Bernstein Joel E | Method and composition for treating pediculosis capitis |
| JPH0252360A (ja) | 1988-08-15 | 1990-02-21 | Fujitsu Ltd | 電子写真感光体 |
| MA21697A1 (fr) * | 1988-12-19 | 1990-07-01 | Dow Agrosciences Llc | Composes de macrolides. |
| US5362634A (en) * | 1989-10-30 | 1994-11-08 | Dowelanco | Process for producing A83543 compounds |
| US5288483A (en) * | 1990-04-18 | 1994-02-22 | The Procter & Gamble Company | Anti-lice treatment compositions |
| DD294255A5 (de) | 1990-05-14 | 1991-09-26 | Adw Forschungsstelle Fuer Chemische Toxikologie,De | Verfahren zur herstellung tetrazolylsubstituierter pyrimidinderivate |
| US5227163A (en) * | 1991-01-18 | 1993-07-13 | Clilco, Ltd. | Lice-repellant compositions |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5539089A (en) * | 1991-11-08 | 1996-07-23 | Dowelanco | A83543 aglycones and pseudoglycones |
| US5202242A (en) * | 1991-11-08 | 1993-04-13 | Dowelanco | A83543 compounds and processes for production thereof |
| US5227295A (en) * | 1991-11-08 | 1993-07-13 | Dowelanco | Process for isolating A83543 and its components |
| JP2613355B2 (ja) | 1992-09-28 | 1997-05-28 | 協和醗酵工業株式会社 | パーキンソン氏病治療剤 |
| US5591606A (en) * | 1992-11-06 | 1997-01-07 | Dowelanco | Process for the production of A83543 compounds with Saccharopolyspora spinosa |
| ES2099604T3 (es) * | 1993-03-12 | 1997-05-16 | Dowelanco | Nuevos compuestos a83543 y procedimiento para su produccion. |
| US5795905A (en) | 1995-06-06 | 1998-08-18 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
| WO1997033883A1 (en) * | 1996-03-13 | 1997-09-18 | Smithkline Beecham Corporation | Novel pyrimidine compounds useful in treating cytokine mediated diseases |
| US6010710A (en) * | 1996-03-29 | 2000-01-04 | Merial | Direct pour-on skin solution for antiparasitic use in cattle and sheep |
| US5952331A (en) * | 1996-05-23 | 1999-09-14 | Syntex (Usa) Inc. | Aryl pyrimidine derivatives |
| US6001981A (en) * | 1996-06-13 | 1999-12-14 | Dow Agrosciences Llc | Synthetic modification of Spinosyn compounds |
| FR2756177B1 (fr) * | 1996-11-28 | 1999-01-29 | Oreal | Dispersion aqueuse de vesicules resistantes a la deshydratation |
| JP2002514195A (ja) | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
| US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| IL130180A0 (en) * | 1996-12-05 | 2000-06-01 | Amgen Inc | Substituted pyrimidine compounds and their use |
| JP2002514196A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジノンおよびピリドン化合物ならびに使用方法 |
| DE19710435A1 (de) * | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
| US5880076A (en) * | 1997-08-04 | 1999-03-09 | Lever Brothers Company, Division Of Conopco, Inc. | Compositions comprising glycacarbamate and glycaurea compounds |
| US6096326A (en) * | 1997-08-15 | 2000-08-01 | Scandinavian-American Import/Export Corporation | Skin care compositions and use |
| JPH11188484A (ja) | 1997-12-25 | 1999-07-13 | Nkk Corp | 多段研削バリ取り装置 |
| CA2315736A1 (en) * | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
| JP3990061B2 (ja) | 1998-01-05 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プリン誘導体および糖尿病の予防・治療剤としてのアデノシンａ２受容体拮抗剤 |
| US6235754B1 (en) * | 1998-01-30 | 2001-05-22 | American Cyanamid Company | Methods and compositions for protecting animals and humans against attack and infestation by arthropod and helminth parasites |
| DE19823397B4 (de) * | 1998-05-26 | 2011-07-28 | Bayer CropScience AG, 40789 | Verwendung von Spinosynen zum Einsatz als Bodeninsektizide |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US6489344B1 (en) * | 1998-06-19 | 2002-12-03 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| CN1129430C (zh) * | 1998-07-02 | 2003-12-03 | 伊莱利利公司 | 控制人虱的制剂 |
| TWI241298B (en) | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
| JP2000126489A (ja) | 1998-10-21 | 2000-05-09 | Purotonikusu Kenkyusho:Kk | 糸又は布と接触するミシン用部品 |
| CA2376835C (en) | 1999-07-02 | 2009-09-15 | Eisai Co., Ltd. | Condensed imidazole compounds and a therapeutic agent for diabetes mellitus |
| KR100521735B1 (ko) * | 2000-02-25 | 2005-10-17 | 에프. 호프만-라 로슈 아게 | 아데노신 수용체 조절인자 |
| EP1136486A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Indanylamino]pyrimidone and 2-[tetrahydronaphthalenylamino]pyrimidone derivatives |
| AU2001248365A1 (en) | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(arylalkylamino)pyrimidone derivatives and 2-(heteroarylalkylamino)pyrimidone derivatives |
| EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| DE60107835T2 (de) * | 2000-04-26 | 2005-12-22 | Eisai Co., Ltd. | Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide |
| EP1308441B1 (en) | 2000-08-11 | 2009-10-07 | Eisai R&D Management Co., Ltd. | 2-aminopyridine compounds and use thereof as drugs |
| AU2001295026B2 (en) | 2000-09-06 | 2008-04-03 | Novartis Vaccines And Diagnostics, Inc. | Inhibitors of glycogen synthase kinase 3 |
| MXPA03002297A (es) * | 2000-09-15 | 2003-06-06 | Vertex Pharma | Compuestos de triazol utiles como inhibidores de proteina cinasa. |
| AU2001292906B2 (en) | 2000-09-19 | 2007-08-16 | Novartis Vaccines And Diagnostics, Inc. | Characterization of the GSK-3beta protein and methods of use thereof |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| TWI330183B (OSRAM) | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
| TWI301834B (en) * | 2001-10-22 | 2008-10-11 | Eisai R&D Man Co Ltd | Pyrimidone compound and pharmaceutical composition including the same |
| AU2002950853A0 (en) | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
| US7538117B2 (en) | 2005-03-21 | 2009-05-26 | Eisai R&D Management Co., Ltd. | Crystalline and amorphous pyrimidine compounds and processes for preparing pyrimidine compounds |
| US7396928B2 (en) | 2005-03-21 | 2008-07-08 | Eisai R&D Management Co., Ltd. | Crystals of 5-[2-amino-4-(2-furyl) pyrimidin-5-yl]-1-methylpyridin-2(1H)-one and processes for preparing the same |
-
2002
- 2002-10-21 TW TW091124227A patent/TWI330183B/zh not_active IP Right Cessation
- 2002-10-22 DE DE60239884T patent/DE60239884D1/de not_active Expired - Lifetime
- 2002-10-22 KR KR1020047005915A patent/KR100884025B1/ko not_active Expired - Fee Related
- 2002-10-22 ES ES02802050T patent/ES2364328T3/es not_active Expired - Lifetime
- 2002-10-22 AT AT02802050T patent/ATE507217T1/de active
- 2002-10-22 DK DK02802050.1T patent/DK1439175T3/da active
- 2002-10-22 US US10/492,905 patent/US7396836B2/en not_active Expired - Fee Related
- 2002-10-22 PL PL370274A patent/PL215572B1/pl not_active IP Right Cessation
- 2002-10-22 MX MXPA04003795A patent/MXPA04003795A/es active IP Right Grant
- 2002-10-22 AU AU2002335536A patent/AU2002335536B2/en not_active Ceased
- 2002-10-22 NZ NZ532373A patent/NZ532373A/en not_active IP Right Cessation
- 2002-10-22 EP EP10173222A patent/EP2246344A1/en not_active Withdrawn
- 2002-10-22 IL IL16149302A patent/IL161493A0/xx unknown
- 2002-10-22 PT PT02802050T patent/PT1439175E/pt unknown
- 2002-10-22 RU RU2004115495/04A patent/RU2288227C2/ru not_active IP Right Cessation
- 2002-10-22 BR BR0213455-1A patent/BR0213455A/pt not_active IP Right Cessation
- 2002-10-22 EP EP02802050A patent/EP1439175B1/en not_active Expired - Lifetime
- 2002-10-22 WO PCT/JP2002/010952 patent/WO2003035639A1/ja not_active Ceased
- 2002-10-22 JP JP2003538155A patent/JP4462930B2/ja not_active Expired - Fee Related
- 2002-10-22 HU HU0401950A patent/HUP0401950A3/hu unknown
- 2002-10-22 CN CNB028209311A patent/CN100519549C/zh not_active Expired - Fee Related
- 2002-10-22 CA CA2463284A patent/CA2463284C/en not_active Expired - Fee Related
-
2004
- 2004-04-16 ZA ZA200402898A patent/ZA200402898B/xx unknown
- 2004-04-19 IL IL161493A patent/IL161493A/en not_active IP Right Cessation
- 2004-04-19 NO NO20041580A patent/NO327581B1/no not_active IP Right Cessation
-
2008
- 2008-03-24 US US12/054,337 patent/US20090030023A1/en not_active Abandoned
-
2011
- 2011-07-11 CY CY20111100672T patent/CY1112341T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200402898B (en) | Pyrimidine compound and medicinal composition thereof | |
| IL153995A0 (en) | 2-aminopyridine derivatives and pharmaceutical compositions containing the same | |
| NO179675C (no) | Pyrimidin-nukleosidderivater og farmasöytisk preparat inneholdende disse | |
| WO2003035640A1 (en) | Pyrimidone compounds and pharmaceutical compositions containing the same | |
| IL154709A0 (en) | Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| MY169840A (en) | Isoxazolines for controlling invertebrate pests | |
| DK289888D0 (da) | 2-substitueret-e-kondenserede oe1,2,4,aatriazolooe1,5-caapyrimidiner, farmaceutiske praeparater og anvendelser deraf | |
| WO2004089366A8 (en) | Bicyclic compounds as nr2b receptor antagonists | |
| DE69324403D1 (de) | Herbizide 2,6-substituierte Pyridine | |
| WO2003028459A8 (de) | Nicotinsäure-heterocyclyl-amide und analogue pyrimidin-derivate als schädlingsbekämpfungsmittel | |
| WO1999031981A3 (de) | Fungizide mischungen auf der basis von pyridincarboxamiden | |
| TW200612920A (en) | Novel imidazolidine derivatives | |
| EP1961734A4 (en) | AMINE CONNECTION AND ITS USE FOR MEDICAL PURPOSES | |
| NO20050498L (no) | CCK-1 reseptormodulatorer | |
| CA2273303A1 (en) | Thienylsulfonylamino(thio)carbonyl compounds | |
| BRPI0418651A (pt) | compostos com base em lisina | |
| KR970069989A (ko) | 피리딘-2,3-디카르복실산 디아미드 유도체 및 유효성분으로 상기 유도체를 함유하는 제초제 | |
| HUP0000366A2 (hu) | Eljárás heterociklusos vegyületek előállítására | |
| PT1492792E (pt) | Derivados de 3-heteroaril-3,5-di-hidro-4-oxo-4h-piridazino(4, 5-b) ao em terapeutica. | |
| WO1999065864A3 (de) | Geminal substituierte amine | |
| NO20055530L (no) | NK-2-antagonistiske basiske lineaere forbindelser og preparater som inneholder dem | |
| DE60239324D1 (de) | Phenyl- und pyridyl-piperidine mit tnf-wirkung | |
| TH65444A (th) | สารประกอบอินทรีย์ | |
| NO20003945L (no) | N-acyl sykliske aminderivater |